[{"orgOrder":0,"company":"Inside Therapeutics","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Inside Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inside Therapeutics \/ Inside Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Inside Therapeutics \/ Inside Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Inside Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : OSE will develop novel RNA therapeutics and delivery methods to fine-tune immune responses in inflammatory disorders and autoimmune diseases, leveraging the advantages of RNA-based therapy.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          May 21, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Recipient : OSE Immunotherapeutics SA

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank